1631 related articles for article (PubMed ID: 24444048)
21. A changing treatment landscape for multiple sclerosis: challenges and opportunities.
Piehl F
J Intern Med; 2014 Apr; 275(4):364-81. PubMed ID: 24444084
[TBL] [Abstract][Full Text] [Related]
22. Update on disease-modifying treatments for multiple sclerosis.
Carrithers MD
Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
[TBL] [Abstract][Full Text] [Related]
23. Current and future therapies targeting the immune system in multiple sclerosis.
Loleit V; Biberacher V; Hemmer B
Curr Pharm Biotechnol; 2014; 15(3):276-96. PubMed ID: 24938888
[TBL] [Abstract][Full Text] [Related]
24. Multiple sclerosis: current knowledge and future outlook.
Kamm CP; Uitdehaag BM; Polman CH
Eur Neurol; 2014; 72(3-4):132-41. PubMed ID: 25095894
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.
Ulzheimer JC; Meuth SG; Bittner S; Kleinschnitz C; Kieseier BC; Wiendl H
BioDrugs; 2010 Aug; 24(4):249-74. PubMed ID: 20623991
[TBL] [Abstract][Full Text] [Related]
26. Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.
Lebrun C; Rocher F
CNS Drugs; 2018 Oct; 32(10):939-949. PubMed ID: 30143945
[TBL] [Abstract][Full Text] [Related]
27. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.
Melzer N; Meuth SG
Clin Exp Immunol; 2014 Mar; 175(3):359-72. PubMed ID: 24032475
[TBL] [Abstract][Full Text] [Related]
28. Immune therapy of multiple sclerosis--future strategies.
Meuth SG; Göbel K; Wiendl H
Curr Pharm Des; 2012; 18(29):4489-97. PubMed ID: 22612746
[TBL] [Abstract][Full Text] [Related]
29. Treatment options for multiple sclerosis: current and emerging therapies.
Gawronski KM; Rainka MM; Patel MJ; Gengo FM
Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
[TBL] [Abstract][Full Text] [Related]
30. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
31. Newer agents in the treatment of multiple sclerosis.
Pawate S; Bagnato F
Neurologist; 2015 Apr; 19(4):104-17. PubMed ID: 25888198
[TBL] [Abstract][Full Text] [Related]
32. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic decision making in a new drug era in multiple sclerosis.
Keegan BM
Semin Neurol; 2013 Feb; 33(1):5-12. PubMed ID: 23709208
[TBL] [Abstract][Full Text] [Related]
34. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
35. Treating multiple sclerosis with monoclonal antibodies: a 2013 update.
Deiß A; Brecht I; Haarmann A; Buttmann M
Expert Rev Neurother; 2013 Mar; 13(3):313-35. PubMed ID: 23448220
[TBL] [Abstract][Full Text] [Related]
36. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
[TBL] [Abstract][Full Text] [Related]
37. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Faulkner M
Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
[TBL] [Abstract][Full Text] [Related]
38. Emerging oral agents for multiple sclerosis.
Fox EJ
Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
